LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "fulminant type" as a keyword



Nivolumab-induced fulminant type 1 diabetes (T1D): the first Italian case report with long follow-up and flash glucose monitoring

Sign Up to like & get
recommendations! Published in 2018 at "Acta Diabetologica"

DOI: 10.1007/s00592-018-1246-4

Abstract: Nivolumab, an Immune Checkpoint Inhibitor (ICI) against programmed death-1 receptors expressed on T-lymphocytes, has been approved by the Food and Drug Administration (FDA) for the treatment of multiple cancers such as Nonsquamous Cell Lung Cancer… read more here.

Keywords: fulminant type; induced fulminant; first italian; nivolumab induced ... See more keywords

Fulminant type 1 diabetes patients display high frequencies of IGRP-specific type 1 CD8+ T cells.

Sign Up to like & get
recommendations! Published in 2021 at "Clinical immunology"

DOI: 10.1016/j.clim.2021.108893

Abstract: The role of cellular autoimmunity in the pathogenesis of fulminant type 1 diabetes (FT1D) remains largely unknown. In this study, we performed an integrated assay using peripheral blood mononuclear cells to determine the islet antigen-specific… read more here.

Keywords: fulminant type; cd8; frequencies igrp; type diabetes ... See more keywords

Drug classes associated with the development of fulminant type 1 diabetes: a retrospective analysis using the FDA adverse event reporting system database

Sign Up to like & get
recommendations! Published in 2025 at "Expert Opinion on Drug Safety"

DOI: 10.1080/14740338.2024.2448202

Abstract: ABSTRACT Background Fulminant type 1 diabetes mellitus (FT1DM) is a severe subtype of type 1 diabetes characterized by rapid onset, metabolic disturbances, and irreversible insulin secretion failure. Recent studies have suggested associations between FT1DM and… read more here.

Keywords: fulminant type; type diabetes; drug; ft1dm ... See more keywords

Tislelizumab-induced fulminant type 1 diabetes mellitus (FT1D): A case report and literature review

Sign Up to like & get
recommendations! Published in 2025 at "Medicine"

DOI: 10.1097/md.0000000000046310

Abstract: Rationale: Immune checkpoint inhibitors, such as tislelizumab, are widely used in oncology but can cause serious immune-related adverse events. Endocrine disorders are common, with fulminant type 1 diabetes mellitus (FT1D) being a rare but life-threatening… read more here.

Keywords: fulminant type; diabetes mellitus; type diabetes; mellitus ft1d ... See more keywords

The Specialty of Emergency Nurse Practitioner Practice: Erratum.

Sign Up to like & get
recommendations! Published in 2018 at "Advanced Emergency Nursing Journal"

DOI: 10.1097/tme.0000000000000182

Abstract: Barbee, M. S., Ogunniyi, A., Horvat, T., & Dang, T. (2015). Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembroluzimab, and nivolumab in oncology. Annals of Pharmacotherapy, 49(8), 907–937. Bristol-Myers Squibb Company.… read more here.

Keywords: fulminant type; journal; anti; type diabetes ... See more keywords
Photo by sammoqadam from unsplash

Glucagon secretions are impaired in patients with fulminant type 1 diabetes

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Diabetes Investigation"

DOI: 10.1111/jdi.13041

Abstract: Arginine‐challenge test in various types of diabetes. read more here.

Keywords: glucagon secretions; fulminant type; impaired patients; type diabetes ... See more keywords
Photo by sammoqadam from unsplash

Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level

Sign Up to like & get
recommendations! Published in 2019 at "Journal of Diabetes Investigation"

DOI: 10.1111/jdi.13143

Abstract: We describe here a case of nivolumab‐induced type 1 diabetes, which developed within 9 days of treatment. The case highlights the importance of frequent monitoring of glucose after initiation of nivolumab treatment. read more here.

Keywords: fulminant type; induced fulminant; diabetes precipitous; type diabetes ... See more keywords

Congenital biliary dilatation appearing 3 years after the correction of duodenal atresia with pancreaticobiliary maljunction

Sign Up to like & get
recommendations! Published in 2020 at "Pediatrics International"

DOI: 10.1111/ped.14323

Abstract: 1 Gu Y, Qng Y, Li P et al. Fulminant type 1 diabetes in children: A multicenter study in China. J. Diabetes Res. 2017; 2017: 6924637. 2 Shiga K, Urakami T, Suzuki J et al.… read more here.

Keywords: dilatation appearing; fulminant type; biliary dilatation; type diabetes ... See more keywords
Photo from wikipedia

Integrative Analyses of Genes Associated with Fulminant Type 1 Diabetes

Sign Up to like & get
recommendations! Published in 2020 at "Journal of Immunology Research"

DOI: 10.1155/2020/1025857

Abstract: Objective Fulminant type 1 diabetes (FT1D) is a type of type 1 diabetes, which is characterized by rapid onset of disease and severe metabolic disorders. We intend to screen for crucial genes and potential molecular… read more here.

Keywords: fulminant type; network; hub genes; type diabetes ... See more keywords

Stevens-Johnson Syndrome/Toxic epidermal necrolysis complicated with fulminant type 1 diabetes mellitus: a case report and literature review

Sign Up to like & get
recommendations! Published in 2024 at "BMC Endocrine Disorders"

DOI: 10.1186/s12902-024-01683-5

Abstract: Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening skin lesion triggered by hypersensitive drug reaction. They are characterized by extensive epidermal necrosis and skin exfoliation. Fulminant type 1 diabetes mellitus (FT1DM)… read more here.

Keywords: johnson syndrome; fulminant type; diabetes mellitus; type diabetes ... See more keywords
Photo by atikahakhtar from unsplash

A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms

Sign Up to like & get
recommendations! Published in 2017 at "European Journal of Dermatology"

DOI: 10.1684/ejd.2016.2923

Abstract: Nivolumab is a monoclonal antibody directed against PD1 (programmed cell death 1) that can improve survival in patients with metastatic melanoma. Such immune checkpoint inhibitors have been known to induce type 1 diabetes mellitus (T1D)… read more here.

Keywords: fulminant type; type diabetes; diabetes mellitus; case fulminant ... See more keywords